CL2018001395A1 - Composiciones farmacéuticas que comprenden amida de levodopa y sus uso - Google Patents
Composiciones farmacéuticas que comprenden amida de levodopa y sus usoInfo
- Publication number
- CL2018001395A1 CL2018001395A1 CL2018001395A CL2018001395A CL2018001395A1 CL 2018001395 A1 CL2018001395 A1 CL 2018001395A1 CL 2018001395 A CL2018001395 A CL 2018001395A CL 2018001395 A CL2018001395 A CL 2018001395A CL 2018001395 A1 CL2018001395 A1 CL 2018001395A1
- Authority
- CL
- Chile
- Prior art keywords
- pharmaceutical compositions
- levodopa
- amide
- levodopa amide
- normation
- Prior art date
Links
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 title abstract 2
- 229960004502 levodopa Drugs 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- -1 levodopa amide Chemical class 0.000 title 1
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 abstract 2
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- 239000002131 composite material Substances 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229960003638 dopamine Drugs 0.000 abstract 1
- 230000007613 environmental effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Psychology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562259324P | 2015-11-24 | 2015-11-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2018001395A1 true CL2018001395A1 (es) | 2018-10-12 |
Family
ID=57590758
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2018001395A CL2018001395A1 (es) | 2015-11-24 | 2018-05-24 | Composiciones farmacéuticas que comprenden amida de levodopa y sus uso |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20170296491A1 (enExample) |
| EP (1) | EP3380076A2 (enExample) |
| JP (1) | JP2018535230A (enExample) |
| CN (1) | CN108495617A (enExample) |
| AU (1) | AU2016358511A1 (enExample) |
| BR (1) | BR112018010564A2 (enExample) |
| CA (1) | CA3006028A1 (enExample) |
| CL (1) | CL2018001395A1 (enExample) |
| IL (1) | IL259484A (enExample) |
| RU (1) | RU2018119194A (enExample) |
| SG (1) | SG11201804395PA (enExample) |
| WO (1) | WO2017090039A2 (enExample) |
| ZA (1) | ZA201803485B (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3116475T3 (pl) | 2014-03-13 | 2021-02-08 | Neuroderm Ltd | Kompozycje inhibitora dekarboksylazy dopa |
| US10258585B2 (en) | 2014-03-13 | 2019-04-16 | Neuroderm, Ltd. | DOPA decarboxylase inhibitor compositions |
| WO2019038637A1 (en) | 2017-08-21 | 2019-02-28 | Neuroderm Ltd | FORMS OF CRYSTALLINE SALT OF LEVODOPA AMIDE AND METHODS OF MAKING AND USING THEM |
| WO2019038639A1 (en) | 2017-08-21 | 2019-02-28 | Neuroderm Ltd | FREE LEOPODOPA CRYSTALLINE AMIDE BASE AND METHODS OF MAKING AND USING SAME |
| WO2019038638A1 (en) | 2017-08-21 | 2019-02-28 | Neuroderm Ltd | PROCESS FOR PREPARING AMIDE OF PURIFIED LEVODOPA |
| WO2019145773A1 (en) | 2017-12-15 | 2019-08-01 | Nos Life Sciences Corporation | Liposomal-encapsulated formulations |
| WO2020178810A1 (en) * | 2019-03-04 | 2020-09-10 | Neuroderm, Ltd. | Pharmaceutical compositions comprising levodopa amide derivatives and uses thereof |
| US11701340B2 (en) * | 2019-04-17 | 2023-07-18 | Vici Health Sciences., Llc | Liquid pharmaceutical compositions |
| PH12022550512A1 (en) * | 2019-09-05 | 2023-09-04 | Neuroderm Ltd | Liquid compositions comprising a levodopa amino acid conjugate and uses thereof |
| JP7506371B2 (ja) * | 2020-01-20 | 2024-06-26 | 国立大学法人浜松医科大学 | ドーパミン減少抑制剤 |
| US11213502B1 (en) | 2020-11-17 | 2022-01-04 | Neuroderm, Ltd. | Method for treatment of parkinson's disease |
| US11844754B2 (en) | 2020-11-17 | 2023-12-19 | Neuroderm, Ltd. | Methods for treatment of Parkinson's disease |
| US11331293B1 (en) | 2020-11-17 | 2022-05-17 | Neuroderm, Ltd. | Method for treatment of Parkinson's disease |
| CN116270675A (zh) * | 2023-03-21 | 2023-06-23 | 山东省分析测试中心 | N-乙酰氨基葡萄糖在防治mptp诱导神经元损伤中的应用 |
| US12161612B2 (en) | 2023-04-14 | 2024-12-10 | Neuroderm, Ltd. | Methods and compositions for reducing symptoms of Parkinson's disease |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004069146A2 (en) | 2003-02-07 | 2004-08-19 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | L-dopa amide derivatives and uses thereof |
| SI2432454T1 (sl) | 2009-05-19 | 2017-09-29 | Neuroderm Ltd | Sestavki za kontinuirano dajanje zaviralcev dopa-dekarboksilaze |
| EP2648716A4 (en) * | 2010-12-10 | 2015-05-20 | Synagile Corp | PRODUCT COMPOSITIONS OF SUVUTABLY PERFUSABLE LÉVODOPA |
| US20150217046A1 (en) * | 2012-06-05 | 2015-08-06 | Synagile Corporation | Dosing regimens for subcutaneously infusible acidic compositions |
-
2016
- 2016-11-23 SG SG11201804395PA patent/SG11201804395PA/en unknown
- 2016-11-23 WO PCT/IL2016/051261 patent/WO2017090039A2/en not_active Ceased
- 2016-11-23 CA CA3006028A patent/CA3006028A1/en not_active Abandoned
- 2016-11-23 CN CN201680079822.0A patent/CN108495617A/zh not_active Withdrawn
- 2016-11-23 JP JP2018526784A patent/JP2018535230A/ja active Pending
- 2016-11-23 BR BR112018010564-3A patent/BR112018010564A2/pt not_active IP Right Cessation
- 2016-11-23 US US15/360,165 patent/US20170296491A1/en not_active Abandoned
- 2016-11-23 EP EP16816418.4A patent/EP3380076A2/en not_active Withdrawn
- 2016-11-23 AU AU2016358511A patent/AU2016358511A1/en not_active Abandoned
- 2016-11-23 RU RU2018119194A patent/RU2018119194A/ru not_active Application Discontinuation
-
2018
- 2018-05-21 IL IL259484A patent/IL259484A/en unknown
- 2018-05-24 CL CL2018001395A patent/CL2018001395A1/es unknown
- 2018-05-25 ZA ZA2018/03485A patent/ZA201803485B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN108495617A (zh) | 2018-09-04 |
| SG11201804395PA (en) | 2018-06-28 |
| EP3380076A2 (en) | 2018-10-03 |
| CA3006028A1 (en) | 2017-06-01 |
| RU2018119194A3 (enExample) | 2020-04-20 |
| JP2018535230A (ja) | 2018-11-29 |
| BR112018010564A2 (pt) | 2018-11-21 |
| IL259484A (en) | 2018-07-31 |
| ZA201803485B (en) | 2019-08-28 |
| RU2018119194A (ru) | 2019-12-25 |
| WO2017090039A3 (en) | 2017-08-31 |
| US20170296491A1 (en) | 2017-10-19 |
| WO2017090039A2 (en) | 2017-06-01 |
| AU2016358511A1 (en) | 2018-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2018001395A1 (es) | Composiciones farmacéuticas que comprenden amida de levodopa y sus uso | |
| HUS2300009I1 (hu) | Karbidopa és L-dopa prodrogok és alkalmazásuk Parkinson-kór kezelésére | |
| CL2020000383A1 (es) | Composiciones de aminoácidos para el tratamiento de lesión neuronal. | |
| ECSP20030074A (es) | Nuevos profármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson | |
| EP3607587A4 (en) | DISPLAY BOARD | |
| CY1120348T1 (el) | Αμiδια ετεροαρυλιου ως αναστολεις της συσσωματωσης πρωτεϊνων | |
| MX383715B (es) | Formas sólidas de acido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acético, composiciones, y usos de las mismas. | |
| CL2020000382A1 (es) | Composiciones de aminoácidos para el tratamiento de enfermedad hepática. | |
| UY36125A (es) | ?Composiciones plaguicidas y métodos relacionados?. | |
| UY35276A (es) | Nuevos compuestos que inhiben la actividad de Lp-PLA2 | |
| EP3699245A4 (en) | INK SET | |
| SI3720433T1 (sl) | Bis-holin tetratiomolibdat za zdravljenje Wilsonove bolezni | |
| HUE059387T2 (hu) | Parkinson-kór kezelése | |
| AR112472A1 (es) | Forma de sales cristalinas de amida de levodopa y métodos para elaborarlas y usarlas | |
| SV2016005306A (es) | Compuestos heteroaromáticos y su uso como ligandos de dopamina d1 | |
| DOP2017000260A (es) | Piroglutamato de vortioxetina | |
| EP3648739A4 (en) | COMPOSITION FOR INJECTION | |
| SV2016005305A (es) | Compuestos heteroaromáticos y su uso como ligandos de dopamina d1 | |
| BR112019000946A2 (pt) | compostos para imagiologia dos agregados da proteína tau | |
| HUE062806T2 (hu) | Vektorok Friedreich-ataxia kezelésére | |
| AR106313A1 (es) | Combinación de levodopa deuterada con carbidopa y opicapona para el tratamiento de enfermedad de parkinson | |
| BR112019007214A2 (pt) | composições do apilimode e métodos para uso do mesmo no tratamento do mal de alzheimer | |
| EP3639842A4 (en) | Pharmaceutical composition containing gly-thymosin 4 (gly-t 4) for treatment of dry eye | |
| SI3413870T1 (sl) | Igmezin za uporabo pri zdravljenju alzheimerjeve bolezni | |
| DOP2016000325A (es) | Compuestos, composición farmacéutica y su uso en el tratamiento de enfermedades neurodegenerativas |